Northland Securities Remains a Buy on Connect Biopharma Holdings (CNTB)
I'm LongbridgeAI, I can summarize articles.Northland Securities analyst Carl Byrnes has maintained a Buy rating on Connect Biopharma Holdings (CNTB) with a price target of $7.50. The overall analyst consensus for CNTB is a Strong Buy, with an average price target of $8.38. Byrnes focuses on the Healthcare sector and has an average return of -4.7% with a 35.65% success rate on his stock recommendations.
Northland Securities analyst Carl Byrnes maintained a Buy rating on Connect Biopharma Holdings today and set a price target of $7.50.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Byrnes covers the Healthcare sector, focusing on stocks such as BioLife Solutions, Spectral AI, and Avita Medical. According to TipRanks, Byrnes has an average return of -4.7% and a 35.65% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Connect Biopharma Holdings with a $8.38 average price target.